Timing of ctDNA Testing in HR+/HER2- Advanced Breast Cancer
ConditionAdvanced Breast Cancer
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGeneplus-Beijing Co. Ltd.
About this trial
This multicenter, prospective observational cohort study aims to investigate the impact of ctDNA level and key actionable gene mutation status on prognosis and treatment response in patients with advanced HR+/HER2- breast cancer.
Eligibility criteria
Qualifiers
Histologically confirmed advanced breast cancer, molecular subtype HR+/HER2-
Age ≥18 years
Expected survival >3 months
Willing to undergo ctDNA testing and sign informed consent form
Disqualifiers
The subject has not signed the informed consent form.
Pregnant or breastfeeding women.
Other situations deemed by the investigator as unsuitable for inclusion in the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov